Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
EPIDAURUSInterventional CardiologyNature MedicineOpen Access

DOAC plus potent P2Y12 increases bleeding without reducing ischemic events versus DOAC, clopidogrel, and aspirin.

View Full Paper
Ask AI
Bookmark
Share

Why the trial?

Patients with atrial fibrillation undergoing PCI for acute coronary syndrome need anticoagulation plus antiplatelet therapy, a combination that trades ischaemic protection against serious bleeding. The optimal early regimen — including escalated single platelet inhibition for one month alongside a NOAC — remained undefined.

Does a 1-month regimen of DOAC plus potent P2Y12 inhibitor reduce recurrent ischemic events and improve safety compared to DOAC plus clopidogrel and in-hospital aspirin in patients with atrial fibrillation and acute coronary syndrome?

Population

602 patients with AF + ACS undergoing PCI (stopped early; 1,474 planned)

Comparison

DOAC + potent P2Y12 (prasugrel/ticagrelor) vs DOAC + clopidogrel + in-hospital ASA

Design

Open-label multicenter randomized trial; win-loss ratio analyses; stopped by DSMB

Follow-up

Primary endpoints at 6 weeks

Key result

In patients with atrial fibrillation and acute coronary syndrome, a 1-month regimen of a DOAC plus a potent P2Y12 inhibitor did not reduce ischemic events (WLR 1.19) but increased bleeding.

Authors

Konstantinos D. RizasKonstantinos D. RizasPresenting authorCross-Cutting CardiologyKMKonstantinos MourouzisDRDominik RathCOChristoph B. Olivier

Discussion

Key questions

No takes yet. Share an insight, caveat, or question.

Where experts stand

Experts see EPIDAURUS as confirming that potent P2Y12 inhibitors should not replace clopidogrel alongside a direct oral anticoagulant in patients with atrial fibrillation and acute coronary syndrome, with the trial stopped early for excess bleeding and no ischemic benefit.

The expert reaction is one-sided: no one defends the experimental strategy, and the early stop for harm cements the view that potent P2Y12 inhibitors paired with an anticoagulant carry unacceptable bleeding risk in this population. Several clinicians stress that clopidogrel remains the appropriate antiplatelet choice. The live question is whether future trials should instead test temporarily pausing the anticoagulant around the acute event rather than escalating antiplatelet potency.

Agreement

Multiple experts agree that the findings do not support routine use of potent P2Y12 inhibitors with direct oral anticoagulants in patients with atrial fibrillation and acute coronary syndrome, and that clopidogrel should remain the standard antiplatelet in this setting.

4 clinicians say this directly

3 takes classified by contention axis so far — the map appears as more land.

Still unclear

Davide Capodanno raises whether the field is asking the wrong question entirely, noting that the next approach being tested is temporarily stopping the oral anticoagulant during the acute phase rather than intensifying antiplatelet therapy. It remains to be seen whether guidelines will formally update their recommendations on the basis of this early-stopped trial, and whether any subgroup might still benefit from short-term potent P2Y12 inhibition.

Key expert perspectives

Davide CapodannoDavide CapodannoInterventional / Structural Cardiology · University of CataniaPractice takeAug 29

The trial confirms expected bleeding harm, but the field may be asking the wrong question entirely

Capodanno notes that the safety stop for excess bleeding with ticagrelor or prasugrel is unsurprising, given what is already known. He challenges whether intensifying antiplatelet therapy was the right approach and points to upcoming trials that instead test temporarily stopping the oral anticoagulant during the acute coronary event.

Distilled from their postX post
CGChristopher GrangerCardiologist, Duke Clinical Research InstitutePractice takeAug 30

Clopidogrel remains the appropriate P2Y12 inhibitor for the majority of these patients

Granger reinforces that clopidogrel should remain the standard antiplatelet agent in this population, a position consistent with current practice that EPIDAURUS now supports with randomized evidence.

Distilled from their postOriginal post
C. Michael GibsonC. Michael GibsonInterventional / Structural Cardiology · Beth Israel Deaconess Medical CenterResults readoutAug 29

Dual antithrombotic therapy with intensified P2Y12 inhibition raised bleeding without reducing ischemic events

Gibson summarizes that in patients with atrial fibrillation and acute coronary syndrome, replacing clopidogrel with prasugrel or ticagrelor alongside a DOAC was associated with higher bleeding risk and no ischemic benefit, leading to early trial termination.

Distilled from 2 of their postsX postX post

Overview

Avoid potent P2Y12 inhibitors with DOAC after PCI in AF; challenges assumptions favoring early intensified antiplatelet therapy.

Key Points

  • Assess the efficacy and safety of a 1-month dual antithrombotic regimen combining direct oral anticoagulants with potent P2Y12 inhibitors versus clopidogrel in patients with atrial fibrillation and acute coronary syndrome.
  • Open-label, randomized controlled trial (EPIDAURUS, NCT04981041) comparing DOAC plus potent P2Y12 inhibitor (prasugrel or ticagrelor) against DOAC plus clopidogrel and in-hospital aspirin.
  • Enrolled N=602 patients (154 female) of a planned 1,474 before premature study termination due to safety concerns raised by the Data and Safety Monitoring Board.
  • Evaluated primary efficacy (recurrent ischemic events) and safety endpoints (death, major bleeding) 6 weeks post-randomization using win-loss ratio analyses.
  • The trial was terminated prematurely after enrolling 602 patients due to safety concerns.
  • Exploratory analyses showed potent P2Y12 inhibitors significantly increased Bleeding Academic Research Consortium (BARC) type ≥2 and ≥3 bleeding.
  • Potent P2Y12 inhibitors demonstrated no clear reduction in recurrent ischemic complications compared to clopidogrel and in-hospital aspirin.

Evidence details

What drove the result?

OutcomePotent P2Y12Clopidogrel
Hierarchical composite: death, stent thrombosis, MI, ischemic stroke, systemic embolism, urgent revascularization
Win-loss ratio 1.19 (95% CI 0.61-2.32; p=0.610) · no clear ischemic benefit; per-arm counts not reported

Limitations & tradeoffs

Safety

BARC type >=2 and >=3 bleeding were higher with the potent P2Y12 inhibitor (secondary endpoints; per-arm counts not reported).

Statistical certainty

premature termination (stopped by the DSMB for safety) at 602 of 1,474 planned patients leaves the trial underpowered.

Subgroup caution

the hierarchical win-loss design makes all subsequent analyses, including bleeding, exploratory.

Representation

only 18% of screened patients met inclusion criteria and agreed to participate.

Design limitations

the statistical design was modified during the course of the trial.

Structured PICO

Does a 1-month regimen of DOAC plus potent P2Y12 inhibitor reduce recurrent ischemic events and improve safety compared to DOAC plus clopidogrel and in-hospital aspirin in patients with atrial fibrillation and acute coronary syndrome?

P
Population
602 patients (median age 78, 25.6% female) with atrial fibrillation and acute coronary syndrome undergoing percutaneous coronary intervention, followed for 6 months.
I
Intervention
1-month regimen of DOAC plus potent P2Y12 inhibitor (prasugrel or ticagrelor)
C
Comparator
DOAC plus clopidogrel and in-hospital aspirin
O
Outcome
Efficacy endpoint (recurrent ischemic events) and safety endpoints (including death and major bleeding), evaluated 6 weeks after randomization using separate win-loss ratio analysescomposite

Main Result

Effect estimate: WLR 1.19 (95% CI 0.61-2.32)

p-value: p=0.610

In patients with atrial fibrillation and acute coronary syndrome, combining a DOAC with a potent P2Y12 inhibitor (prasugrel or ticagrelor) increases bleeding risk without reducing ischemic events compared to a regimen of DOAC plus clopidogrel.

Limitations

  • Prematurely terminated after enrollment of 602 of 1,474 patients due to safety concerns.
  • Hierarchical win-loss ratio approach means subsequent analyses are exploratory.
  • Standalone bleeding complications were secondary endpoints.
  • Selection of escalated P2Y12 inhibitor and factor Xa inhibitor was at the discretion of the treating physician.
  • All patients underwent peri-interventional loading with aspirin.
  • Only 18% of screened patients met the inclusion criteria and agreed to participate.
  • Statistical design was modified during the course of the trial.
  • Prematurely terminated after enrollment of 602 of an expected 1,474 patients

Coverage & sources

Journal, society, and media accounts. Useful signal, not independent expert judgment.

Cite This Study

Rizas et al. (2026) conducted an RCT in Atrial fibrillation and acute coronary syndrome (n=602). DOAC plus potent P2Y12 inhibitor (prasugrel or ticagrelor) vs. DOAC plus clopidogrel and in-hospital aspirin was evaluated on Hierarchic composite of death, stent thrombosis, myocardial infarction, ischemic stroke, systemic thromboembolism and urgent revascularization (WLR 1.19, 95% CI 0.61-2.32, p=0.610). In patients with atrial fibrillation and acute coronary syndrome, a 1-month regimen of a DOAC plus a potent P2Y12 inhibitor did not reduce ischemic events (WLR 1.19) but increased bleeding.

synapsesocial.com/papers/6a8fbb6317152b56e6b6481dhttps://doi.org/10.1038/s41591-026-04629-7
View Full Paper
Ask AI
Bookmark
Share